MA09.03 Plasma Proteomics-based Models for Predicting Immunotherapy- and Chemotherapy-Related Toxicity in NSCLC Patients
Naidoo, Jarushka Gandara, David Chae, Young Kwan Carbone, David Christopoulos, Petros Brown, Sean
Naidoo, Jarushka
Gandara, David
Chae, Young Kwan
Carbone, David
Christopoulos, Petros
Brown, Sean
Glos Author
Date
2024-10-16
Journal Title
Subject
Type
Conference Abstract
Collections
Abstract
Patients with metastatic non-small cell lung cancer (NSCLC) are typically treated with PD-1/PD-L1-based immune checkpoint inhibitors (ICIs) depending on tumor characteristics and line of therapy. Toxicities resulting from such treatments can substantially affect quality of life and treatment trajectory. Currently, there are no reliable biomarkers for predicting the development of ICI-induced immune-related adverse events (irAEs) and chemotherapy-related adverse events (chemo-AEs). Here, we describe plasma proteomics-based models for the pretreatment prediction of severe irAEs, specific irAEs and chemo-AEs in patients with NSCLC.
Citation
Naidoo, J., Gandara, D. R., Sullivan, R. R., Chae, Y. K., Carbone, D., Christopoulos, P., ... & Elon, Y. (2024). MA09. 03 Plasma Proteomics-based Models for Predicting Immunotherapy-and Chemotherapy-Related Toxicity in NSCLC Patients. Journal of Thoracic Oncology, 19(10), S87-S88.